Member Info for AquaeSulis01

What's the relevance to an antibody test Sloppy/

"The tests are designed to identify if a person is currently infected with coronavirus."

I suspect lack of hedging had more to do with the fact that an EPS of a novel fracture basement play made prediction of future output too difficult to determine a hedging % , after all, the company still can't confidently say what they will produce next month let alone next year

Trice

Strange you assign the blame for lack of hedging to Dr Trove rather than the Kerogen board member who after all represented the shareholder group with the most to lose f rom the oil price drop

Absolutely agree Jimzi, let's wait for the procession of factual RNS over the coming months which should send the sp steadily Northwards

He also said you had immunity for 1 or 2 years so believe what you want

Summary from H&L

WOOD GROUP SEES 19% FALL IN INTERIM EARNINGS
(Sharecast News) - Wood Group said it expected a 19% fall in first half core earnings as the coronavirus pandemic hammered the oil and gas sector.
The energy industry engineer said adjusted earnings before interest, tax, depreciation and amortisation in a range of $295m - $305m and operating profit before exceptionals of around $80m - $90m. Like-for-like revenue was down around 11%.

The order book at the end of May was $7bn, down about 11% since December 2019, of which about $3.5bn was due to be delivered in 2020, Wood said on Friday, adding that margins contracted by 70 basis points on a like-for-like basis.

"The global engineering and consultancy market is facing unique and unparalleled challenges in 2020 from Covid-19 and volatility in oil prices," said chief executive Robin Watson.

"The relative strength we are seeing in chemicals & downstream, the built environment and renewables, where we will double our revenues in 2020, is helping to mitigate the impact of challenging conditions in upstream and midstream oil & gas."

Wood said it had made taken measures in the second quarter that were expected to deliver more than $200m in full year overhead cost savings.

The company added that it had a strong balance sheet and liquidity and expected a fall in net debt at June 30 from $1.43bn at December 2019 after first quarter disposals.

notready, yes it may lead to more regular tests but until the below is resolved, it may also lead to a much lower uptake is all I am cautioning.

Though the study is small, the researchers noted the findings may spur some world leaders to rethink issuing so-called “immunity passports.” Some countries have considered issuing passports or risk-free certificates to people who have antibodies against Covid-19, enabling them to travel or return to work assuming that they are protected against reinfection.

ne critical question among scientists is whether antibodies produced in response to Covid-19 offer protection against getting infected again. Additionally, scientists are still unsure of how long immunity lasts if antibodies do provide protection.

In general, antibodies that help the body fight off infections are produced in response to invading foreign particles or antigens. Vaccines work by inducing the immune system to produce these molecules. Health officials have said there is not enough data to indicate that coronavirus antibodies ensure immunity against the virus.

Prythee, I admire your optimism

https://www.cnbc.com/2020/06/18/coronavirus-antibodies-may-last-only-2-to-3-months-after-infection-study-suggests.html

"Lots of positive news flow ahead with contracts, details of the Covid antibody tests that he said can be scaled to 6000 tests/day from the current 3000 tests/day. The 3000 tests/day fetches £12m pa. So we could potentially looking at £18-24m on the Quotient partnership alone" If Cathal pulls this off whilst the length of any immunity to reinfection has yet to be established, then hats off to him. I believe having an antibody test on tap is crucial for OO so that they can properly screen volunteers for the upcoming COVID19 Human Challenge study, but how successful OO will be in selling tests to Companies until there is research to prove that people have "an immunity passport" is open to question. But as you say, there are shedloads of other positives for this company and I am heavily invested here

Orderbook down $1bn from $8bn to $7bn

Well that's good to hear andinio, after all it will make a change to see RNS's published announcing an increase in II holdings rather than selling them down but don't let facts get in the way eh

and if he wants to attract IIs rather than pis he needs to keep his pitch factual, after all he does have a good story to tell but he doesn't want that story conveyed as a fable

I agree that 2 mths may be even better especially as this is the first time that I have seen any research that confirms that having antibodies will protect against reinfection. However, if Cathal wants to be seen as credible, he does need to check his facts

Enjoyed the interview but Cathal does need to reign in the claims that immunity for people who have antibodies last for at least a year; latest research does at least suggest immunity for at least two months after infection.

https://www.sciencefocus.com/news/coronavirus-immunity-appears-to-last-for-at-least-two-months-after-diagnosis/

Bigbear as you seem to thrive on risk (after all next update may be negative or positive as you recognise) you could place a big bet on Japan in 3:00 at Royal Ascot today and instantly double your money

The piperperson, you miss th e point I was making re the drug. Of course a vaccine is needed and to speed up permission to test the vaccines through human challenge studies you need to deris k the deliberate infection of volunteers as much as possible hence good news for OO I would suggest.

Excellent news that there is a drug to treat serious cases of Covid19, should pave the way for Clinical trials to take place.

Prime Minister Boris Johnson has hailed "the biggest breakthrough yet" in the search for a coronavirus treatment, after researchers at Oxford Unversity confirmed that a widely-available drug can save lives.

Speaking at the daily Downing Street press conference, Mr Johnson said: "This drug, dexamethasone, can now be made available across the NHS. And we've taken steps to ensure we have enough supplies even in the event of a second peak."

Mr Johnson added: "There is genuine cause to celebrate a remarkable British scientific achievement."

Dexamethasone is a steroid drug which was first developed 60 years ago. Researchers have confirmed that it can reduce the symptoms of the Covid-19 virus for people with breathing difficulties, at a cost of around £5 per patient.

Oxford University said the results of a trial revealed that dexamethasone "reduces death by up to one third in hospitalised patients with severe respiratory complications of Covid-19."

The clinical trial, which involved more than 11,500 patients across 175 NHS hospitals found that it "reduced deaths by one-third in ventilated patients ... and by one fifth in other patients receiving oxygen only".

The drug does not stop Covid-19 spreading or prevent people from catching it.

Research into the drug was led Peter Horby, professor of emerging infectious diseases in the Nuffield Department of Medicine at University of Oxford. He also took part in the press conference, saying: "It's available throiughout the world and it's exttremely cheap."

Prof Horby added: "It is really good news that we've now got a treatment that almost every patient can take."

Padrock "how can you take advantage of this predictable SP movement? By buying now before this predictable announcement arrives I would suggest

Parob, the price has just returned to where it was last month before the forced sell of the Opti shareholding; there has been no further deals since then so will remain under the radar until any further deals or news on current deal progression.